Stephen F. Hodi

Oncology · 2009–2017

A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

Whom Stephen F. Hodi trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Pardoll (in Oncology)

Who trusts Stephen F. Hodi

  1. Antoni Ribas (in Oncology)

Papers from Stephen F. Hodi's perspective

Ordered by how strongly the researchers Stephen F. Hodi trusts endorse each paper. Same corpus, a different order for every researcher.

  1. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  3. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
  4. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. (Immunity)
  5. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. (Blood)
  6. PD-L2 is a second ligand for PD-1 and inhibits T cell activation (Nature Immunology)
  7. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (Nature Medicine)
  8. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  9. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
  10. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (Clinical Cancer Research)

Their papers